SH-PTP1 Inhibitors

NSC 87877 is a selective inhibitor of SH-PTP1, characterized by its ability to form stable complexes with the enzyme's active site. This compound engages in specific hydrogen bonding and hydrophobic interactions, which effectively disrupts the phosphatase's catalytic function. Its unique structural features facilitate a distinct conformational change in the enzyme, altering its reaction kinetics and influencing downstream signaling pathways. Additionally, NSC 87877 demonstrates favorable solubility, enhancing its accessibility to target proteins.

Sodium Stibogluconate, a SH2 domain-containing protein tyrosine phosphatase inhibitor, directly inhibits SH-PTP1 activity by binding to its active site.

PTP Inhibitor I acts as a potent modulator of SH-PTP1 by selectively binding to its active site, leading to a significant alteration in enzyme conformation. This compound exhibits unique electrostatic interactions that stabilize the enzyme-inhibitor complex, effectively hindering substrate access. Its kinetic profile reveals a marked decrease in phosphatase activity, impacting cellular signaling cascades. Furthermore, PTP Inhibitor I's distinct molecular architecture contributes to its specificity and interaction dynamics with target proteins.

3,4-Dephostatin is a selective inhibitor of SH-PTP1, characterized by its ability to form stable hydrogen bonds with key residues in the enzyme's active site. This interaction induces a conformational shift that disrupts the enzyme's catalytic function. The compound's unique structural features enhance its binding affinity, resulting in altered reaction kinetics and a pronounced reduction in phosphatase activity, thereby influencing downstream signaling pathways. Its distinct molecular interactions underscore its specificity in targeting SH-PTP1.

Acts as a phosphatase inhibitor, vanadate inhibits SH-PTP1 by mimicking phosphate groups and competing for binding at the enzyme's active site.

Ethyl-3,4-Dephostatin acts as a potent inhibitor of SH-PTP1, showcasing a unique ability to engage in hydrophobic interactions with the enzyme's active site. This compound's structural configuration allows for effective steric hindrance, preventing substrate access and modulating enzymatic activity. Its selective binding alters the enzyme's conformational dynamics, leading to significant changes in phosphatase turnover rates and impacting cellular signaling cascades. The compound's specificity is highlighted by its tailored interactions with SH-PTP1.

As a cAMP phosphodiesterase inhibitor, Perphenazine increases cAMP levels, indirectly reducing SH-PTP1 activity by promoting protein kinase A-mediated inhibitory phosphorylation.

PTP Inhibitor II functions as a selective antagonist of SH-PTP1, characterized by its ability to form strong hydrogen bonds with key residues in the enzyme's active site. This interaction stabilizes a unique conformation that disrupts the phosphatase's catalytic cycle. The compound's kinetic profile reveals a slow-onset inhibition, allowing for prolonged modulation of enzymatic activity. Its distinct molecular architecture enhances binding affinity, influencing downstream signaling pathways.

PTP Inhibitor V, known as PHPS1, exhibits a remarkable selectivity for SH-PTP1 through its unique ability to engage in hydrophobic interactions with specific amino acid side chains within the enzyme's active site. This compound induces a conformational shift that effectively hinders substrate access, thereby altering the enzyme's reaction kinetics. Its structural features promote a stable complex formation, impacting cellular signaling cascades and regulatory mechanisms.

2-Chloro-2',4'-difluoroacetophenone acts as a selective inhibitor of SH-PTP1 by forming strong non-covalent interactions with the enzyme's active site. Its unique halogen substituents enhance electron-withdrawing effects, facilitating specific hydrogen bonding and dipole-dipole interactions. This compound's steric properties contribute to a distinct binding affinity, effectively modulating the enzyme's catalytic activity and influencing downstream signaling pathways.